Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» hepatocellular carcinoma
hepatocellular carcinoma
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
Endpoints
Merck
FDA
complete response letter
Keytruda
Eisaid
Lenvima
hepatocellular carcinoma
Roche
Flag link:
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
Flag link:
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
BioSpace
AstraZeneca
Imfinzi
orphan drugs
FDA
hepatocellular carcinoma
Flag link:
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Pharmaforum
Eli Lilly
Cyramza
FDA
liver cancer
hepatocellular carcinoma
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
CP Wire
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
RNAi
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
Flag link:
AZ begins liver cancer immunotherapy tie-up with AVEO
AZ begins liver cancer immunotherapy tie-up with AVEO
Pharmaforum
AstraZeneca
Aveo Oncology
cancer immunotherapy
Imfinzi
Fotivda
hepatocellular carcinoma
Flag link:
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck gets FDA okay for Keytruda as liver cancer therapy
Pharmaforum
Merck
Keytruda
FDA
hepatocellular carcinoma
liver cancer
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai
Merck
Lenvima
liver cancer
hepatocellular carcinoma
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
CP WIre
Eisai
Merck
Lenvima
hepatocellular carcinoma
Europe
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:
Eisai-Merck partnership picks up first-line Lenvima approval
Eisai-Merck partnership picks up first-line Lenvima approval
Biopharma Dive
FDA
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:
Bayer growth hope Stivarga boosts survival in liver cancer patients
Bayer growth hope Stivarga boosts survival in liver cancer patients
Fierce Pharma
Bayer
Stivarga
liver cancer
Nexavar
hepatocellular carcinoma
Flag link:
FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Yahoo
Can-Fite BioPharma
CF102
FDA
fast track
hepatocellular carcinoma
liver cancer
Flag link:
Isis/AstraZeneca Expand Antisense Technology Collaboration
Isis/AstraZeneca Expand Antisense Technology Collaboration
Yahoo/Zacks
AstraZeneca
Isis Pharmaceuticals
antisense
ISIS-STAT3Rx
hepatocellular carcinoma
prostate cancer
ISIS-ARRx
Flag link:
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
Pipeline Review
TSU-68
Taiho Pharmaceutical
hepatocellular carcinoma
Flag link:
Celsion Stock Blown Apart On Thermodox Phase III Data
Celsion Stock Blown Apart On Thermodox Phase III Data
Seeking Alpha
Celsion
ThermoDox
hepatocellular carcinoma
Flag link:
ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib
ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib
Yahoo/Fly on the Wall
Arqule
tivantinib
hepatocellular carcinoma
Flag link:
Pages
1
2
next ›
last »